Download (direct link):
Baneyx, F. (1999). Recombinant protein expression in E. coli. Curr. Opin. Biotechnol. 10, 411-421.
Carrio, M. & Villaverde, A. (2002). Construction and deconstruction of bacterial inclusion bodies. J. Biotechnol. 96(1), 3-12.
Datar, R. et al. (1993). Process economics of animal cell and bacterial fermentations: a case study analysis of tissue plasminogen activator. Bio/Technology 11, 340-357.
Fischer, R. et al. (1999). Towards molecular farming in the future: using plant cell suspension cultures as bioreactors. Biotechnol Appl. Biochem. 30, 109-112.
Helmrich, A. & Barnes, D. (1998). Animal cell culture equipment and techniques. Methods Cell Biol. 57, 3-17.
Houdebine, L. (2000). Transgenic animal bioreactors. Transgen. Res. 9(4-5), 305-320.
Hu, W. & Peshwa, M. (1993). Mammalian cells for pharmaceutical manufacturing. Am. Soc. Microbiol. News 59, 65-68.
Larrick, J. & Thomas, D. (2001). Producing proteins in transgenic plants and animals. Curr. Opin. Biotechnol. 12(4), 411-418.
La Vallie, E. et al. (1993). A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Bio/Technology 11, 187-193.
Mason, H. et al. (2002). Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol. Med. 8(7), 324-329.
Punt, P. et al. (2002). Filamentous fungi as cell factories for heterologous protein production. Trends Biotechnol. 20, 5, 200-206.
Rosen, J. et al. (1996). The mammary gland as a bioreactor: factors resulting in the efficient expression of milk protein-based transgenes. Am. J. Clin. Nutr. 63, 627S-632S.
Varley, J & Birch, J. (1999). Reactor design for large scale suspension animal cell culture. Cytotechnology 29(3), 177-205.
Wright, G. et al. (1991). High level expression of active human arantitrypsin in the milk of transgenic sheep. Bio/ Technology 9, 830-834.
Purification, characterization, formulation
Arakawa, T. et al. (2001). Factors effecting short-term and long-term stabilities of proteins. Adv. Drug Delivery Rev. 46, 307-326.
Bernard, A. et al. (1996). Downstream processing of insect cultures. Cytotechnology 20(1-3), 239-257.
Cleland, J. et al. (1993). The development of stable protein formulations: a close look at protein aggregation, deamidation and oxidation. Crit. Rev. Therapeut. Drug Carrier Syst. 10(4), 307-377.
Ding, J. & Ho, B. (2001). A new era in pyrogen testing. Trends Biotechnol. 18(8), 277-280
Geisow, M. (1991). Characterizing recombinant proteins. Bio/Technology 9, 921-924.
Hoglund, M. (1998). Glycosylated and non-glycosylated recombinant human granulocyte colony stimulating factor (rhG-CSF)—what is the difference? Med. Oncol. 15(4), 229-233.
Hu, S. & Dovichi, N. (2002). Capillary electrophoresis for the analysis of biopolymers. Anal. Chem. 74(12) 2833-2850.
Kakehi, K. et al. (2002). Analysis of glycoproteins and the oligosaccharides thereof by high performance capillary electrophoresis — significance in regulatory studies on biopharmaceutical products. Bio Chromatogr. 16(2), 103-115.
Keller, K. et al. (2001). The bioseparation needs for tomorrow. Trends Biotechnol. 19(11), 438-441.
Lee, J. (2000). Biopharmaceutical formulation. Curr. Opin. Biotechnol. 11(1), 81-84.
Mann, M. et al. (2001). Analysis of proteins and proteomes by mass spectrometry. Ann Rev. Biochem. 70, 437-473.
Ullao-Aguirre, A. et. al. (1999). Role of glycosylation in function of follicle-stimulating hormone. Endocrinology 11(3), 205-215.
Wang, W. (2000). Lyophilization and development of solid protein pharmaceuticals. International J. Pharmaceut. 203(1-2), 1-60.
Wei, W. (1999). Instability, stabilization and formulation of liquid protein pharmaceuticals. Int. J. Pharmaceut. 185(2), 129-188.
Willey, K. (1999). An elusive role for glycosylation in the structure and function of reproductive hormones. Hum. Reprod. Update 5(4), 330-335.
THE DRUG MANUFACTURING PROCESS 187
Regulation and validation
Chew, N. (1993). Validation of biopharmaceutical processes. Pharmaceut. Technol. Eur. 5(11), 34-39.
Dabbah, R. & Grady, L. (1998). Pharmacopoeial harmonization in biotechnology. Curr. Opin. Biotechnol. 9, 307-311. Darling, A. (2002). Validation of biopharmaceutical purification processes for virus clearance evaluation. Mol. Biotechnol. 21(1), 57-83.
Glennon, B. (1997). Control system validation in multipurpose biopharmaceutical facilities. J. Biotechnol. 59(1-2), 53-61.
Lubiniecki, A. (1998). Biopharmaceutical regulation—progress and challenges. Curr. Opin. Biotechnol. 9, 305-306. Seamon, K. (1998). Specifications for biotechnology-derived protein drugs. Curr. Opin. Biotechnol. 9, 319-325.
The cytokines— the interferon family
Cytokines are a diverse group of regulatory proteins or glycoproteins whose classification remains somewhat confusing, (Table 4.1). These molecules are normally produced in minute quantities by the body. They act as chemical communicators between various cells, inducing their effect by binding to specific cell surface receptors, thereby triggering various intracellular signal transduction events.